Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1996;94:911-921

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Antman, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antman, E. M.

(Circulation. 1996;94:911-921.)
© 1996 American Heart Association, Inc.


Articles

Hirudin in Acute Myocardial Infarction

Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial

Elliott M. Antman, MD; for the TIMI 9B Investigators*

the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.

Correspondence to Elliott M. Antman, MD, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

Background The TIMI 9 trial evaluated whether the direct antithrombin hirudin is more effective than an indirect-acting antithrombin, heparin, as adjunctive therapy for thrombolysis in myocardial infarction.

Methods and Results Patients (n=3002) with acute myocardial infarction were treated with aspirin and either accelerated-dose tissue plasminogen activator (TPA) or streptokinase. They were randomized within 12 hours of symptoms to receive either intravenous heparin (5000 U bolus followed by infusion of 1000 U/h) or hirudin (0.1 mg/kg bolus followed by infusion of 0.1 mg/kg per hour). The infusions of both antithrombins were titrated to a target activated partial thromboplastin time (aPTT) of 55 to 85 seconds and were administered for 96 hours. Patients randomized to hirudin were significantly more likely to have an aPTT measurement in the target range (P<.0001). The primary end point (death, recurrent nonfatal myocardial infarction, or development of severe congestive heart failure or cardiogenic shock by 30 days) occurred in 11.9% of the 1491 patients in the heparin group and 12.9% of the 1511 patients in the hirudin group (P=NS). Subgroup analyses did not reveal any profile of patients who benefited more from one of the antithrombins. The rate of major hemorrhage was similar in the heparin (5.3%) and hirudin (4.6%) groups; intracranial hemorrhage occurred in 0.9% of the heparin and 0.4% of the hirudin patients.

Conclusions Heparin and hirudin have an equal effect as adjunctive therapy to TPA and streptokinase in preventing unsatisfactory outcome in patients with acute myocardial infarction. Similar rates of major bleeding were observed for patients in the heparin and hirudin groups.


Key Words: heparin • thrombolysis • myocardial infarction




This article has been cited by other articles:


Home page
ChestHome page
J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz
Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 141S - 159S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 257S - 298S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 708S - 775S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726.
[Full Text] [PDF]


Home page
CirculationHome page
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Circulation, December 19, 2006; 114(25): 2871 - 2891.
[Full Text] [PDF]


Home page
NEJMHome page
E. M. Antman, D. A. Morrow, C. H. McCabe, S. A. Murphy, M. Ruda, Z. Sadowski, A. Budaj, J. L. Lopez-Sendon, S. Guneri, F. Jiang, et al.
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
N. Engl. J. Med., April 6, 2006; 354(14): 1477 - 1488.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Meurin, J. Y. Tabet, H. Weber, N. Renaud, and A. B. Driss
Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement
Circulation, January 31, 2006; 113(4): 564 - 569.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. R. Sinnaeve, J. Simes, S. Yusuf, J. Garg, S. Mehta, J. Eikelboom, J. A. Bittl, P. Serruys, E. J. Topol, and C. B. Granger
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention
Eur. Heart J., November 2, 2005; 26(22): 2396 - 2403.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. B. Gibler, C. P. Cannon, A. L. Blomkalns, D. M. Char, B. J. Drew, J. E. Hollander, A. S. Jaffe, R. L. Jesse, L. K. Newby, E. M. Ohman, et al.
Practical Implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the Emergency Department: A Scientific Statement From the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers
Circulation, May 24, 2005; 111(20): 2699 - 2710.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. S. Sabatine, D. A. Morrow, R. P. Giugliano, P. B.J. Burton, S. A. Murphy, C. H. McCabe, C. M. Gibson, and E. Braunwald
Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes
Circulation, April 26, 2005; 111(16): 2042 - 2049.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. H. Mehta, C. B. Granger, K. P. Alexander, E. Bossone, H. D. White, and M. H. Sketch Jr
Reperfusion strategies for acute myocardial infarction in the elderly: Benefits and risks
J. Am. Coll. Cardiol., February 15, 2005; 45(4): 471 - 478.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Hirsh, M. O'Donnell, and J. I. Weitz
New anticoagulants
Blood, January 15, 2005; 105(2): 453 - 463.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Hirsh and R. Raschke
Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 188S - 203S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. I. Weitz, J. Hirsh, and M. M. Samama
New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 265S - 286S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 549S - 575S.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Bates and J. I. Weitz
Emerging Anticoagulant Drugs
Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1491 - 1500.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, J. Karha, S. A. Murphy, D. James, D. A. Morrow, C. P. Cannon, R. P. Giugliano, E. M. Antman, E. Braunwald, and TIMI Study Group
Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials
J. Am. Coll. Cardiol., July 2, 2003; 42(1): 7 - 16.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Eikelboom, H. White, and S. Yusuf
The evolving role of direct thrombin inhibitors in acute coronary syndromes
J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 70S - 78S.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. S. Rathore, K. P. Weinfurt, C. P. Gross, and H. M. Krumholz
Validity of a Simple ST-Elevation Acute Myocardial Infarction Risk Index: Are Randomized Trial Prognostic Estimates Generalizable to Elderly Patients?
Circulation, February 18, 2003; 107(6): 811 - 816.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al.
Management of acute myocardial infarction in patients presenting with ST-segment elevation
Eur. Heart J., January 1, 2003; 24(1): 28 - 66.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
H.-U. Esslinger, S. Kohne, P. Radziwon, J. M. Walenga, and H. K. Breddin
Effects of PEG-Hirudin in Clotting Parameters and Platelet Function and its Interaction with Aspirin in Healthy Volunteers
Clinical and Applied Thrombosis/Hemostasis, January 1, 2003; 9(1): 79 - 88.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. N. Berry, G. Lassalle, C. Lunven, J.-M. Altenburger, F. Guilbert, A. Lale, J.-P. Herault, C. Lecoffre, C. Pfersdorff, J.-M. Herbert, et al.
SSR182289A, a Novel, Orally Active Thrombin Inhibitor: In Vitro Profile and ex Vivo Anticoagulant Activity
J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1189 - 1198.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. E. Freedman, R. C. Becker, J. E. Adams, S. Borzak, R. L. Jesse, L. K. Newby, P. O'Gara, J. C. Pezzullo, R. Kerber, B. Coleman, et al.
Medication Errors in Acute Cardiac Care: An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke
Circulation, November 12, 2002; 106(20): 2623 - 2629.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
W. F. Baker Jr
Thrombolytic Therapy
Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314.
[PDF]


Home page
CirculationHome page
H. U. Jones, J. B. Muhlestein, K. W. Jones, T. L. Bair, F. Lavasani, M. Sohrevardi, B. D. Horne, D. Doty, and D. L. Lappe
Preoperative Use of Enoxaparin Compared With Unfractionated Heparin Increases the Incidence of Re-Exploration for Postoperative Bleeding After Open-Heart Surgery in Patients Who Present With an Acute Coronary Syndrome: Clinical Investigation and Reports
Circulation, September 24, 2002; 106(12_suppl_1): I-19 - I-22.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. K.C. Chan, J. Rak, L. Berry, P. Liao, M. Vlasin, J. Weitz, and P. Klement
Antithrombin-Heparin Covalent Complex: A Possible Alternative to Heparin for Arterial Thrombosis Prevention
Circulation, July 9, 2002; 106(2): 261 - 265.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Nurs.Home page
D. Wehby
A simple risk index accurately predicted mortality in patients with ST elevation myocardial infarction
Evid. Based Nurs., July 1, 2002; 5(3): 90 - 90.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S.H. Baird, I.B.A. Menown, S.J. Mcbride, T.G. Trouton, and C. Wilson
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction
Eur. Heart J., April 2, 2002; 23(8): 627 - 632.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. R Prieto, H. Ma, R. Huang, G. Khan, K. A Schwartz, E. E Hage-Korban, A. H Schmaier, J. M Davis, A. A.K Hasan, and G. S Abela
Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury
Cardiovasc Res, March 1, 2002; 53(4): 984 - 992.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. I. Weitz and H. R. Buller
Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future
Circulation, February 26, 2002; 105(8): 1004 - 1011.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. P. Cannon, A. Battler, R. G. Brindis, J. L. Cox, S. G. Ellis, N. R. Every, J. T. Flaherty, R. A. Harrington, H. M. Krumholz, M. L. Simoons, et al.
American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Emergency Physicians, American Heart Association, Cardiac Society of Australia & New Zealand, National Heart Foundation of Australia, Society for Cardiac Angiography and Interventions, and the Taiwan Society of Cardiology
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2114 - 2130.
[Full Text] [PDF]


Home page
CirculationHome page
A. M. Ross, P. Molhoek, C. Lundergan, M. Knudtson, Y. Draoui, L. Regalado, V. Le Louer, F. Bigonzi, W. Schwartz, E. de Jong, et al.
Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II)
Circulation, August 7, 2001; 104(6): 648 - 652.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. Llevadot, R. P. Giugliano, and E. M. Antman
Bolus Fibrinolytic Therapy in Acute Myocardial Infarction
JAMA, July 25, 2001; 286(4): 442 - 449.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
H. Van Aken, C. Bode, H. Darius, C. Diehm, A. Encke, D. C. Gulba, S. Haas, W. Hacke, W. Puhl, M. Quante, et al.
State-of-the-Art Review: Anticoagulation: The Present and Future
Clinical and Applied Thrombosis/Hemostasis, July 1, 2001; 7(3): 195 - 204.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster
Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
A. G. G. Turpie and E. M. Antman
Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes
Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster
Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Circulation, June 19, 2001; 103(24): 2994 - 3018.
[Full Text] [PDF]


Home page
CirculationHome page
E. M. Antman
The Search for Replacements for Unfractionated Heparin
Circulation, May 8, 2001; 103(18): 2310 - 2314.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
G. N. Levine, M. N. Ali, and A. I. Schafer
Antithrombotic Therapy in Patients With Acute Coronary Syndromes
Arch Intern Med, April 9, 2001; 161(7): 937 - 948.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. C. Bahit, E. J. Topol, R. M. Califf, P. W. Armstrong, D. A. Criger, V. Hasselblad, A. Betriu, J. Hirsh, D. Ardissino, and C. B. Granger
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb
J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1001 - 1007.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Greinacher and N. Lubenow
Recombinant Hirudin in Clinical Practice : Focus on Lepirudin
Circulation, March 13, 2001; 103(10): 1479 - 1484.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. W. Armstrong, C. Granger, and F. Van de Werf
Bolus Fibrinolysis : Risk, Benefit, and Opportunities
Circulation, February 27, 2001; 103(8): 1171 - 1173.
[Full Text] [PDF]


Home page
CirculationHome page
J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas
Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris
Circulation, February 6, 2001; 103(5): 658 - 663.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Chest, January 1, 2001; 119(1_suppl): 64S - 94S.
[Full Text] [PDF]


Home page
ChestHome page
J. I. Weitz and J. Hirsh
New Anticoagulant Drugs
Chest, January 1, 2001; 119(1_suppl): 95S - 107S.
[Full Text] [PDF]


Home page
ChestHome page
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade
Antithrombotic Agents in Coronary Artery Disease
Chest, January 1, 2001; 119(1_suppl): 228S - 252S.
[Full Text] [PDF]


Home page
ChestHome page
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest, January 1, 2001; 119(1_suppl): 253S - 277S.
[Full Text] [PDF]


Home page
Eur Heart JHome page
E.M Antman, C.M Gibson, J.A de Lemos, R.P Giugliano, C.H McCabe, P Coussement, I Menown, C.A Nienaber, T.C Rehders, M.J Frey, et al.
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14
Eur. Heart J., December 1, 2000; 21(23): 1944 - 1953.
[Abstract] [PDF]


Home page
CirculationHome page
D. A. Morrow, E. M. Antman, A. Charlesworth, R. Cairns, S. A. Murphy, J. A. de Lemos, R. P. Giugliano, C. H. McCabe, and E. Braunwald
TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation : An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy
Circulation, October 24, 2000; 102(17): 2031 - 2037.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Eichler, H.-J. Friesen, N. Lubenow, B. Jaeger, and A. Greinacher
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance
Blood, October 1, 2000; 96(7): 2373 - 2378.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al.
ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina)
J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062.
[Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
D. Longrois, E. de Maistre, N. Bischoff, C. Dopff, C. Meistelman, M. Angioi, and T. Lecompte
Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia
Can J Anesth, March 1, 2000; 47(3): 255 - 260.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Pernerstorfer, U. Hollenstein, J.-B. Hansen, P. Stohlawetz, H.-G. Eichler, S. Handler, W. Speiser, and B. Jilma
Lepirudin blunts endotoxin-induced coagulation activation
Blood, March 1, 2000; 95(5): 1729 - 1734.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. P. McRedmond, P. Harriott, B. Walker, and D. J. Fitzgerald
Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1
Blood, February 15, 2000; 95(4): 1301 - 1308.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. F. Kong, E. J. Topol, J. A. Bittl, H. D. White, P. Theroux, V. Hasselblad, and R. M. Califf
Clinical Outcomes of Bivalirudin for Ischemic Heart Disease
Circulation, November 16, 1999; 100(20): 2049 - 2053.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Oldgren, R. Linder, L. Grip, A. Siegbahn, and L. Wallentin
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease
Eur. Heart J., November 2, 1999; 20(22): 1657 - 1666.
[Abstract] [PDF]


Home page